UBS raised the firm’s price target on Dillard’s (DDS) to $175 from $170 and keeps a Sell rating on the shares. Dillard’s Q2 report is likely a positive stock catalyst, but not a thesis changer, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DDS:
